YahooSeptember 15, 2026 at 10:15 AM NYLast Month
BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full Population
BioVie (NASDAQ:BIVI) shares fell nearly 9. 7% in premarket trading after the company reported results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for neurological symptoms associated with Long COVID.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
